2 generation of CD14 + -derived DCs are described in the section 'Cell collection and preparation'. EBV-transformed lymphoblastoid cell lines (EBV-LCL) were generated using standard procedures and cultured in 10% heat-inactivated FCS supplemented IMDM. 1 PHA (phytohemagglutinin)-blasts were generated by incubating PB-MNC in IMDM supplemented with 10% heat-inactivated ABOS, 100 IU/ml IL-2 and 800 ng/ml PHA-HA16 for seven days after which the PHA-blasts were used in assays. Additionally, third party primary leukemic cell samples (AML, B-ALL, and CLL) expressing the mismatched HLA-DP molecules were selected from the Leiden University Medical Center Biobank for Hematological diseases.
Skin derived human fibroblasts 2 were cultured up to 90% confluency in DMEM (Lonza) supplemented with 10% heat-inactivated FCS and were pre-treated for 4 days with 200 IU/ml IFNγ to upregulate HLA-class II expression. K562 (chronic myelogenous leukemia, cultured in 10% FCS IMDM), HeLa (cervical cancer, cultured in 10% FCS IMDM), WiDR (colon adenocarcinoma, cultured in 10% FCS IMDM), EGI-1 (bile duct carcinoma, cultured in 10% FCS MEM (Lonza) supplemented with 1mM Sodium Pyruvate, 2x MEM Amino Acids and 2x MEM non-essential Amino Acids (Thermo Fisher Scientific, Waltham, MA, USA)) cell lines were retrovirally transduced to induce expression of specific HLA-DP molecules. Different HLA-DP alleles were cloned into a pLZRS retroviral vector (an empty pLZRS retroviral vector was used as a mock vector for our control cell lines) and the constructs were verified by sequencing. To retrovirally transduce the different cell lines, Retronectin (recombinant human fibronectin, r-fibronectin, Takara Bio USA, Mountain View, CA, USA) was used. 3
Recognition assay
The clonality of expanded T cell clones was confirmed by TCR Vβ repertoire-analysis using the IOTest® Beta Mark kit (Beckman Coulter Life Sciences, Indianapolis, Indiana, USA). To investigate the recognition profile of the expanded T cell clones, 2,000 T cells were exposed in a 384-well culture plate to different autologous and allogeneic HLA-DP expressing hematopoietic cells (DCs, EBV-LCL, CD14 + monocytes, PHA-blasts, K562 transduced with HLA-DP alleles, AML, B-ALL or CLL) in a 1:5 responder to stimulator ratio, and to autologous and allogeneic HLA-DP expressing third party fibroblasts and tissue cell lines transduced with HLA-DP alleles (HeLa's, WiDR, and EGI-1) in a 1:3 responder to stimulator ratio. The supernatants were harvested after overnight incubation of the cells in 10% ABOS IMDM supplemented with 25 IU/ml IL-2, and the amount of IFNγ in the supernatants was 3 quantified using standard enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Sanquin Reagents, Amsterdam, The Netherlands). The cytotoxic capacity of a proportion of reactive allo-HLA-DP restricted CD4 T cell clones was confirmed using quantitative FACS analysis of cytotoxicity 2 or by using 51 Cr-release assay 4 .
Flow cytometric analyses
At the initiation and restimulation of the allo-HLA-DP specific immune responses, the percentages of CD3 + TCRαβ + T cells were measured in the responder population to determine the correct ratio of stimulation. 
